Martinez et al. studied the frequency and spectrum of PIK3CA somatic mutations in breast cancer according to subtype, showing that the prevalence of PIK3CA mutations in ER-negative/HER2-negative, HER2-positive, and ER-positive/HER2-negative breast cancer, was 18%, 22%, and 37%, respectively. This evidence concerns the gene ERBB2 and breast carcinoma.